Sangamo BioSciences, Inc. Announces Conference Call And Webcast To Discuss Global Collaboration With Biogen Idec, Inc. (California) To Develop Treatments For Hemoglobinopathies
Published: Jan 09, 2014
RICHMOND, Calif., Jan. 9, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) will host a teleconference at 8:30 am ET today, Thursday, January 9, 2014, to discuss its global collaboration with Biogen Idec to develop ZFP Therapeutics for hemoglobinopathies.
A live webcast of the call can be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under Events and Presentations. A replay of the webcast will also be available for two weeks after the call.
The call will be open to the public: dial-in numbers are 877-377-7553 for domestic callers and 678-894-3968 for international callers. The passcode for the call is 32012653. A replay will be available from approximately 11:30 a.m. ET on January 9, 2014 to 11:59 p.m. ET on January 16, 2014. The conference call replay numbers for domestic and international callers are 855-859-2056 and 404-537-3406, respectively. The conference ID number for the replay is 32012653.
Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 and Phase1/2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. As part of its acquisition of Ceregene Inc., Sangamo acquired a fully-enrolled and funded, double-blind, placebo-controlled Phase 2 trial to evaluate NGF-AAV (CERE-110) in Alzheimer's disease. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia, Huntington's disease and hemoglobinopathies such as sickle cell disease and beta-thalassemia. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo has entered into a strategic collaboration with Shire AG to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation.
ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.
SOURCE Sangamo BioSciences, Inc.
Help employers find you! Check out all the jobs and post your resume.